About trametinib dimethyl sulfoxide
MEK inhibitor anticancer medicine
Used for
- Treats certain melanomas with BRAF V600 mutations, usually with dabrafenib.
- Treats certain BRAF-mutated lung cancers and other tumors with dabrafenib.
- Treats certain low-grade gliomas in children, sometimes without dabrafenib.
Usual adult dose
Usually 2 mg by mouth once daily; dose and use depend on cancer and combination treatment.
Usual dose in children
For children at least 1 year old: dose based on body weight, once daily; specialist-directed.
Common side effects
- Rash and other skin problems
- Diarrhea, nausea, or vomiting
- Fever, chills, or fatigue
- Swelling, bleeding, or high blood pressure
Important warnings
- Can cause heart problems, eye disorders, lung inflammation, or serious skin reactions.
- Fever can become severe, especially with dabrafenib.
- May cause bleeding, blood clots, or bowel perforation.
- Requires monitoring; follow prescribed dosing and preparation instructions.
Pregnancy
Can harm an unborn baby. Effective contraception is recommended during treatment and for 4 months after the last dose.
Breastfeeding
Do not breastfeed during treatment and for 4 months after the last dose.
Interactions
- Some medicines can change trametinib exposure; review all medicines with the oncology team.
- Dabrafenib is commonly combined with trametinib and affects treatment planning.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.